ClinicalTrials.gg
CompletedNCT05765344Updated Jan 26, 2026Results posted

Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function

A Phase 1 interventional study of Bulevirtide and Bulevirtide in Hepatic Impairment and Healthy, sponsored by Gilead Sciences. Completed at 6 sites in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
74
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal and impaired hepatic (liver) function.

02

Conditions studied

  • Hepatic Impairment
  • Healthy
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

All individuals:

  • (BMI) of 18 ≤ BMI ≤ 40 kg/m\^2 at screening.
  • Have a calculated (CLcr) of at least 60 mL/min (using the Cockcroft-Gault method) based on serum creatinine and actual body weight as measured at screening.
  • Individuals assigned male at birth and individuals assigned female at birth and of who engage in heterosexual intercourse must agree to use protocol-specified method(s) of as described in the protocol.
  • Individuals have not donated blood within 56 days of study entry or plasma within 7 days of study entry and must refrain from blood donation from clinic admission, throughout the study period, and continuing for at least 30 days following the last dose of study drug.
  • 12-lead (ECG) evaluations at screening must be without abnormalities as assessed by the investigator.
  • Aside from hepatic impairment among the individuals with hepatic impairment, the individual must, in the opinion of the investigator, be sufficiently healthy for study participation based upon medical history, physical examination, vital signs, and screening laboratory evaluations.
  • Must be willing and able to comply with all study requirements.

Individuals With Hepatic Impairment:

  • Have a diagnosis of chronic (> 6 months), stable hepatic impairment (moderate or severe based upon the -Turcotte (CPT) classification system for moderate or severe hepatic impairment [CPT Class B or C, respectively]) with no clinically significant change in hepatic status (as determined by the investigator) within the 2 months (60 days) prior to screening.

    • Individuals with moderate or severe hepatic impairment must have a score of 7 to 9 or 10 to 15 on the CPT classification system at screening. If an individual's score changes during the study, the score at screening will be used for classification.
  • Must meet all of the following laboratory parameters at screening:

    • (ALT) ≤ 10 × (ULN)
    • aspartate aminotransferase (AST) ≤ 10 × ULN
    • ≥ 25,000/mm\^3
    • ≥ 9 g/dL
  • Individuals with hepatic impairment who have not been on a stable dose of concomitant medications for at least 4 weeks prior to screening (or 5 half-lives, whichever is longer) and/or for whom dose changes are likely to occur during the study should have their medications reviewed and approved by the sponsor.

Matched Control Individuals With Normal Hepatic Function:

  • Have alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, , and total at or below the ULN; and albumin above the lower limit of normal at screening and at admission.
  • Must be matched for age (± 10 years), sex (assigned at birth), and BMI (± 20%, 18 ≤ BMI ≤ 40 kg/m\^2) with an individual in the hepatic impairment group.

Key Exclusion Criteria:

All Individuals:

  • Positive serum pregnancy test at screening and at admission.
  • Breastfeeding individual.
  • Have received any study drug within 30 days prior to study dosing.
  • Have current alcohol or substance abuse judged by the investigator to potentially interfere with individual compliance or individual safety, or a positive drug or alcohol test at screening or admission.
  • Have poor venous access that limits phlebotomy.
  • Have been treated with systemic , therapies, or chemotherapeutic agents within 3 months prior to screening or is expected to receive these agents during the study.
  • Have a history of any of the following:

    • Significant serious skin disease, such as but not limited to rash, food allergy, eczema, psoriasis, or urticaria.
    • Significant drug sensitivity or drug allergy (such as anaphylaxis or hepatoxicity).
    • Known to the study drugs, their metabolites, or to formulation .
    • Significant cardiac disease (including history of myocardial infarction based on ECG and/or clinical history, any history of ventricular tachycardia, congestive heart failure, or dilated cardiomyopathy with ≤ 40%); or a family history of long syndrome, or unexplained death in an otherwise healthy individual between the ages of 1 and 30 years.
    • Syncope, palpitations, or unexplained dizziness.
    • Implanted defibrillator or pacemaker.
  • Have any serious or active medical or psychiatric illness (including depression).
  • Requirement for ongoing therapy with or prior use of any prohibited medications listed in the protocol.

Individuals With Hepatic Impairment:

  • Have a positive test result for (HIV) antibody, surface antigen (HBsAg), or virus (HCV) antibody with detectable HCV ribonucleic acid (RNA) at screening.
  • Suspicion of hepatocellular carcinoma (ie, if alpha-fetoprotein > 20 ng/mL at screening).
  • Anticipated changes in concomitant medications or dosage used to treat symptoms of hepatic impairment or associated comorbid conditions that could lead to clinically significant changes in medical conditions during the study.
  • Use of known hepatotoxic medications, clinical organic anion transporting polypeptide (OATP)1B1/3 inhibitors, or sodium-taurocholate cotransporting polypeptide (NTCP) inhibitors (half-maximal inhibitory concentration (IC50) or kinetic inhibition constant [Ki] \< 20 μM).
  • Positive test for drugs of abuse, including alcohol at screening or admission, with the exception of opioids and tetrahydrocannabinol (marijuana) under prescription and verified by the investigator as for pain management.

Matched Control Individuals With Normal Hepatic Function:

  • Have a positive test result for HIV antibody, HBsAg, or HCV antibody.
  • Have a history of liver disease including Gilbert's disease.
  • Have taken any prescription medications or over-the-counter medications, including herbal products, within 28 days prior to start of study drug dosing, with the exception of vitamins and/or acetaminophen and/or ibuprofen and/or hormonal contraceptive medications.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Group A: Bulevirtide (BLV) 2 mg, Moderate Hepatic Impairment

    Participants with moderate hepatic impairment will receive BLV 2 mg subcutaneous (SC) injection, once daily for 6 days starting on Day 1.

    Drug: Bulevirtide

  • Experimental
    Group A: BLV 2 mg, Matched Control

    Control group participants with normal hepatic function matched similar to moderate hepatic impairment participants will receive BLV 2 mg SC injection once daily for 6 days starting on Day 1.

    Drug: Bulevirtide

  • Experimental
    Group B: BLV 2 mg, Severe Hepatic Impairment

    Participants with severe hepatic impairment will receive BLV 2 mg SC injection, once daily for 6 days starting on Day 1.

    Drug: Bulevirtide

  • Experimental
    Group B: BLV 2 mg, Matched Control

    Control group participants with normal hepatic function matched similar to moderate hepatic impairment participants will receive BLV 2 mg SC injection once daily for 6 days starting on Day 1.

    Drug: Bulevirtide

  • Experimental
    Group C: BLV 10 mg, Moderate Hepatic Impairment

    Participants with moderate hepatic impairment will receive BLV 10 mg SC injection, once daily for 6 days starting on Day 1.

    Drug: Bulevirtide

  • Experimental
    Group C: BLV 10 mg, Matched Control

    Control group participants with normal hepatic function matched similar to moderate hepatic impairment participants will receive BLV 10 mg SC injection once daily for 6 days starting on Day 1.

    Drug: Bulevirtide

  • Experimental
    Group D: BLV 10 mg, Severe Hepatic Impairment

    Participants with severe hepatic impairment will receive BLV 10 mg SC injection, once daily for 6 days starting on Day 1.

    Drug: Bulevirtide

  • Experimental
    Group D: BLV 10 mg, Matched Control

    Control group participants with normal hepatic function matched similar to moderate hepatic impairment participants will receive BLV 10 mg SC injection once daily for 6 days starting on Day 1.

    Drug: Bulevirtide

Interventions

  • 2 mg administered via subcutaneous injections.

    Also known as: Hepcludex®, Myrcludex B

  • 10 mg administered via subcutaneous injections.

    Also known as: Hepcludex®, Myrcludex B

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: AUCtau of Bulevirtide (BLV)

    AUCtau was defined as the area under the concentration versus time curve (AUC) over the dosing interval at steady state.

    Time frame: Day 6: Predose and up to 24 hours postdose

  2. PK Parameter: Cmax,ss of BLV

    Cmax,ss was defined as the maximum observed concentration of drug at steady state.

    Time frame: Day 6: Predose and up to 24 hours postdose

Secondary outcomes

  1. PK Parameter: AUC0-24h of BLV

    AUC0-24h was defined as the partial area under the concentration versus time curve from time zero to time 24 hours.

    Time frame: Day 1: Predose and up to 24 hours postdose

  2. PK Parameter: Tmax of BLV

    Tmax was defined as the time (observed time point) of Cmax.

    Time frame: Days 1 and 6: Predose and up to 24 hours postdose

  3. PK Parameter: Cmax of BLV

    Cmax was defined as the maximum observed plasma concentration of drug.

    Time frame: Day 1: Predose and up to 24 hours postdose

  4. PK Parameter: t1/2 of BLV

    t1/2 was defined as estimate of the terminal elimination half-life of the drug in plasma, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).

    Time frame: Day 6: Predose and up to 48 hours postdose

  5. PK Parameter: CLss/F of BLV

    CLss/F was defined as the apparent clearance at the steady state (CLss) after administration of the drug: CLss/F = Dose/AUCtau, where "Dose" is the dose of the drug per interval.

    Time frame: Day 6: Predose and up to 48 hours postdose

  6. PK Parameter: Vss/F of BLV

    Vss/F was defined as the apparent steady-state volume of distribution of the drug.

    Time frame: Day 6: Predose and up to 48 hours postdose

  7. Pharmacodynamic (PD) Parameter: Ctrough of Total Bile Acids (BA)

    Ctrough was defined as the concentration of total BA at the end of the dosing interval.

    Time frame: Predose on Days 2, 3, 4, 5, 7, and 8

  8. PD Parameter: Cmax of Total BA

    Cmax was defined as the maximum observed concentration of total BA.

    Time frame: Days 1 and 6: Predose and up to 24 hours postdose

  9. PD Parameter: AUC0-24h of Total BA

    AUC0-24 was defined as the partial area under the concentration versus time curve from time "0" to time "24" hours for total BA.

    Time frame: Days 1 and 6: Predose and up to 24 hours postdose

  10. PD Parameter: NetAUC of Total BA

    NetAUC was defined as the positive portion of area under the baseline-adjusted biomarker concentration versus time curve over the dosing interval.

    Time frame: Days 1 and 6: Predose and up to 24 hours postdose

  11. PD Parameter: Tmax of Total BA

    Tmax was defined as the time (observed time point) of Cmax of total BA.

    Time frame: Days 1 and 6: Predose and up to 24 hours postdose

  12. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug. If the AE onset date is the same as the date of study drug start date then the AE onset time must be on or after the study drug start time. If the AE onset time is missing when the start dates were the same, the AE were considered treatment emergent. An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment.

    Time frame: First dose date up to Day 6 plus 30 days

  13. Percentage of Participants With Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. If the relevant baseline laboratory value is missing, any abnormality of at least Grade 1 observed within the time frame specified above will be considered treatment emergent. Grading categories are determined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening; Grade 5: Death.

    Time frame: First dose date up to Day 6 plus 30 days

07

Results

Posted Jan 26, 2026

Participant flow

Participants were enrolled at study sites in the United States.

Participant flow — Overall Study
MilestoneGroup A: Bulevirtide (BLV) 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
Started111188101088
Completed101088101088
Not completed11000000
Withdrew: Protocol violation11000000

Outcome measures

PrimaryPharmacokinetic (PK) Parameter: AUCtau of Bulevirtide (BLV)

AUCtau was defined as the area under the concentration versus time curve (AUC) over the dosing interval at steady state.

Time frame:
Day 6: Predose and up to 24 hours postdose
Reported as:
Mean · h*ng/mL
Pharmacokinetic (PK) Parameter: AUCtau of Bulevirtide (BLV)
h*ng/mLGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
Pharmacokinetic (PK) Parameter: AUCtau of Bulevirtide (BLV)152 ± 110150 ± 66.9215 ± 71.7113 ± 45.81270 ± 7761560 ± 3471520 ± 4591600 ± 502
Statistical analysis
  • Group A: BLV 2 mg, Moderate Hepatic Impairment vs Group A: BLV 2 mg, Matched Control · Geometric least-squares mean ratio (%): 87.2 · 90% CI 49.4 to 154ANOVA model with hepatic function as fixed effect was fitted to natural log-transformed values of the multiple dose PK parameter under evaluation. Geometric least-squares mean ratio (%) and 90%CI for hepatic impairment versus control were calculated.
  • Group B: BLV 2 mg, Severe Hepatic Impairment vs Group B: BLV 2 mg, Matched Control · Geometric least-squares mean ratio (%): 197 · 90% CI 138 to 281ANOVA model with hepatic function as fixed effect was fitted to natural log-transformed values of the multiple dose PK parameter under evaluation. Geometric least-squares mean ratio (%) and 90%CI for hepatic impairment versus control were calculated.
  • Group C: BLV 10 mg, Moderate Hepatic Impairment vs Group C: BLV 10 mg, Matched Control · Geometric least-squares mean ratio (%): 73.4 · 90% CI 54.4 to 99.2ANOVA model with hepatic function as fixed effect was fitted to natural log-transformed values of the multiple dose PK parameter under evaluation. Geometric least-squares mean ratio (%) and 90%CI for hepatic impairment versus control were calculated.
  • Group D: BLV 10 mg, Severe Hepatic Impairment vs Group D: BLV 10 mg, Matched Control · Geometric least-squares mean ratio (%): 95.8 · 90% CI 73.1 to 126ANOVA model with hepatic function as fixed effect was fitted to natural log-transformed values of the multiple dose PK parameter under evaluation. Geometric least-squares mean ratio (%) and 90%CI for hepatic impairment versus control were calculated.
PrimaryPK Parameter: Cmax,ss of BLV

Cmax,ss was defined as the maximum observed concentration of drug at steady state.

Time frame:
Day 6: Predose and up to 24 hours postdose
Reported as:
Mean · ng/mL
PK Parameter: Cmax,ss of BLV
ng/mLGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
PK Parameter: Cmax,ss of BLV29.5 ± 23.822.7 ± 14.761.4 ± 27.615.2 ± 6.64175 ± 113261 ± 64.1293 ± 96.8263 ± 101
Statistical analysis
  • Group A: BLV 2 mg, Moderate Hepatic Impairment vs Group A: BLV 2 mg, Matched Control · Geometric least-squares mean ratio (%): 117 · 90% CI 67.1 to 205ANOVA model with hepatic function as fixed effect was fitted to natural log-transformed values of the multiple dose PK parameter under evaluation. Geometric least-squares mean ratio (%) and 90%CI for hepatic impairment versus control were calculated.
  • Group B: BLV 2 mg, Severe Hepatic Impairment vs Group B: BLV 2 mg, Matched Control · Geometric least-squares mean ratio (%): 401 · 90% CI 271 to 593ANOVA model with hepatic function as fixed effect was fitted to natural log-transformed values of the multiple dose PK parameter under evaluation. Geometric least-squares mean ratio (%) and 90%CI for hepatic impairment versus control were calculated.
  • Group C: BLV 10 mg, Moderate Hepatic Impairment vs Group C: BLV 10 mg, Matched Control · Geometric least-squares mean ratio (%): 58.3 · 90% CI 40.8 to 83.3ANOVA model with hepatic function as fixed effect was fitted to natural log-transformed values of the multiple dose PK parameter under evaluation. Geometric least-squares mean ratio (%) and 90%CI for hepatic impairment versus control were calculated.
  • Group D: BLV 10 mg, Severe Hepatic Impairment vs Group D: BLV 10 mg, Matched Control · Geometric least-squares mean ratio (%): 114 · 90% CI 80.7 to 161ANOVA model with hepatic function as fixed effect was fitted to natural log-transformed values of the multiple dose PK parameter under evaluation. Geometric least-squares mean ratio (%) and 90%CI for hepatic impairment versus control were calculated.
SecondaryPK Parameter: AUC0-24h of BLV

AUC0-24h was defined as the partial area under the concentration versus time curve from time zero to time 24 hours.

Time frame:
Day 1: Predose and up to 24 hours postdose
Reported as:
Mean · h*ng/mL
PK Parameter: AUC0-24h of BLV
h*ng/mLGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
PK Parameter: AUC0-24h of BLV82.9 ± 55.254.0 ± 12.8174 ± 77.951.2 ± 8.90672 ± 434850 ± 3371220 ± 350750 ± 376
SecondaryPK Parameter: Tmax of BLV

Tmax was defined as the time (observed time point) of Cmax.

Time frame:
Days 1 and 6: Predose and up to 24 hours postdose
Reported as:
Median · hours
PK Parameter: Tmax of BLV
hoursGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
Day 11.50 (0.500 to 3.00)1.48 (1.00 to 2.00)1.00 (0.983 to 1.50)1.50 (1.00 to 2.03)4.00 (1.00 to 9.00)5.00 (2.00 to 9.00)3.00 (1.50 to 4.00)5.00 (1.50 to 9.00)
Day 61.38 (0.500 to 1.60)1.51 (1.03 to 3.00)1.02 (1.00 to 1.50)1.75 (1.00 to 3.00)3.00 (3.00 to 6.00)3.00 (2.00 to 4.00)2.50 (2.00 to 3.00)3.00 (2.97 to 4.00)
SecondaryPK Parameter: Cmax of BLV

Cmax was defined as the maximum observed plasma concentration of drug.

Time frame:
Day 1: Predose and up to 24 hours postdose
Reported as:
Mean · ng/mL
PK Parameter: Cmax of BLV
ng/mLGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
PK Parameter: Cmax of BLV23.7 ± 15.212.6 ± 4.2857.7 ± 24.212.4 ± 3.8499.2 ± 94.3127 ± 65.6230 ± 85.4103 ± 69.6
SecondaryPK Parameter: t1/2 of BLV

t1/2 was defined as estimate of the terminal elimination half-life of the drug in plasma, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).

Time frame:
Day 6: Predose and up to 48 hours postdose
Reported as:
Mean · hours
PK Parameter: t1/2 of BLV
hoursGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
PK Parameter: t1/2 of BLV3.34 ± 1.312.86 ± 0.6862.31 ± 0.7915.05 ± 2.393.49 ± 1.152.80 ± 0.7952.78 ± 0.7503.33 ± 0.975
SecondaryPK Parameter: CLss/F of BLV

CLss/F was defined as the apparent clearance at the steady state (CLss) after administration of the drug: CLss/F = Dose/AUCtau, where "Dose" is the dose of the drug per interval.

Time frame:
Day 6: Predose and up to 48 hours postdose
Reported as:
Mean · L/h
PK Parameter: CLss/F of BLV
L/hGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
PK Parameter: CLss/F of BLV22.1 ± 13.915.8 ± 7.219.97 ± 2.4619.8 ± 7.209.63 ± 3.886.70 ± 1.627.06 ± 1.986.76 ± 2.10
SecondaryPK Parameter: Vss/F of BLV

Vss/F was defined as the apparent steady-state volume of distribution of the drug.

Time frame:
Day 6: Predose and up to 48 hours postdose
Reported as:
Mean · liters
PK Parameter: Vss/F of BLV
litersGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
PK Parameter: Vss/F of BLV119 ± 10070.7 ± 46.334.4 ± 16.1148 ± 78.852.6 ± 33.527.8 ± 13.928.4 ± 11.934.5 ± 19.4
SecondaryPharmacodynamic (PD) Parameter: Ctrough of Total Bile Acids (BA)

Ctrough was defined as the concentration of total BA at the end of the dosing interval.

Time frame:
Predose on Days 2, 3, 4, 5, 7, and 8
Reported as:
Mean · uM
Pharmacodynamic (PD) Parameter: Ctrough of Total Bile Acids (BA)
uMGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
Day 226.5 ± 27.14.68 ± 3.06223 ± 1315.18 ± 4.7950.6 ± 55.125.7 ± 19.6158 ± 60.531.0 ± 25.5
Day 346.3 ± 49.77.96 ± 7.00213 ± 1326.60 ± 2.7467.2 ± 70.922.6 ± 9.53180 ± 69.429.5 ± 25.1
Day 441.9 ± 50.56.86 ± 3.58192 ± 1216.03 ± 5.3257.3 ± 46.023.3 ± 14.8157 ± 87.116.1 ± 8.68
Day 530.5 ± 23.37.65 ± 3.85201 ± 1197.96 ± 6.0150.6 ± 26.225.1 ± 12.2176 ± 96.123.7 ± 13.9
Day 738.2 ± 37.310.2 ± 5.55170 ± 91.38.44 ± 7.6880.7 ± 65.921.8 ± 13.7222 ± 97.025.9 ± 16.0
Day 833.4 ± 37.46.76 ± 5.62151 ± 82.05.69 ± 3.7337.1 ± 53.17.29 ± 3.73129 ± 78.911.0 ± 9.21
SecondaryPD Parameter: Cmax of Total BA

Cmax was defined as the maximum observed concentration of total BA.

Time frame:
Days 1 and 6: Predose and up to 24 hours postdose
Reported as:
Mean · uM
PD Parameter: Cmax of Total BA
uMGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
Day 146.6 ± 61.415.6 ± 15.4317 ± 15613.1 ± 4.30176 ± 99.7145 ± 44.5305 ± 40.9150 ± 72.0
Day 6124 ± 11785.5 ± 42.2318 ± 97.962.9 ± 44.6343 ± 134180 ± 35.8370 ± 51.7221 ± 78.9
SecondaryPD Parameter: AUC0-24h of Total BA

AUC0-24 was defined as the partial area under the concentration versus time curve from time "0" to time "24" hours for total BA.

Time frame:
Days 1 and 6: Predose and up to 24 hours postdose
Reported as:
Mean · uM*h
PD Parameter: AUC0-24h of Total BA
uM*hGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
Day 1766 ± 1010195 ± 1745870 ± 2930168 ± 69.52270 ± 14401690 ± 3485130 ± 9181760 ± 748
Day 61840 ± 17901000 ± 3915680 ± 2010720 ± 4724640 ± 20102330 ± 5276840 ± 12502920 ± 1150
SecondaryPD Parameter: NetAUC of Total BA

NetAUC was defined as the positive portion of area under the baseline-adjusted biomarker concentration versus time curve over the dosing interval.

Time frame:
Days 1 and 6: Predose and up to 24 hours postdose
Reported as:
Mean · uM*h
PD Parameter: NetAUC of Total BA
uM*hGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
Day 1259 ± 345133 ± 1541790 ± 1430113 ± 66.91880 ± 10201630 ± 3342380 ± 7811690 ± 731
Day 6768 ± 773925 ± 3921880 ± 1120657 ± 4674210 ± 14102270 ± 5424030 ± 12202850 ± 1140
SecondaryPD Parameter: Tmax of Total BA

Tmax was defined as the time (observed time point) of Cmax of total BA.

Time frame:
Days 1 and 6: Predose and up to 24 hours postdose
Reported as:
Median · hours
PD Parameter: Tmax of Total BA
hoursGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
Day 19.08 (-0.500 to 12.0)9.00 (6.00 to 23.5)7.50 (4.00 to 12.0)12.0 (6.00 to 24.7)12.0 (6.00 to 12.0)10.5 (6.00 to 12.1)12.0 (6.00 to 12.0)10.6 (9.00 to 12.0)
Day 66.02 (1.50 to 12.0)9.00 (6.00 to 12.0)7.50 (6.00 to 12.0)10.5 (4.00 to 12.1)12.0 (6.00 to 12.0)9.00 (3.00 to 12.0)12.0 (6.00 to 12.1)10.5 (6.00 to 12.0)
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug. If the AE onset date is the same as the date of study drug start date then the AE onset time must be on or after the study drug start time. If the AE onset time is missing when the start dates were the same, the AE were considered treatment emergent. An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment.

Time frame:
First dose date up to Day 6 plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)27.39.125.012.520.020.025.025.0
SecondaryPercentage of Participants With Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. If the relevant baseline laboratory value is missing, any abnormality of at least Grade 1 observed within the time frame specified above will be considered treatment emergent. Grading categories are determined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening; Grade 5: Death.

Time frame:
First dose date up to Day 6 plus 30 days
Reported as:
Number · percentage of participants
Percentage of Participants With Laboratory Abnormalities
percentage of participantsGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
Any Grade 1 or Higher63.663.6100.062.590.090.075.050.0
Grade 3 or 40.00.00.00.010.00.025.00.0

Adverse events

Collected over Up to Day 6 plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A: BLV 2 mg, Moderate Hepatic Impairment0/11 (0%)0/11 (0%)3/11 (27.3%)
Group A: BLV 2 mg, Matched Control0/11 (0%)0/11 (0%)1/11 (9.1%)
Group B: BLV 2 mg, Severe Hepatic Impairment0/8 (0%)0/8 (0%)2/8 (25%)
Group B: BLV 2 mg, Matched Control0/8 (0%)0/8 (0%)1/8 (12.5%)
Group C: BLV 10 mg, Moderate Hepatic Impairment0/10 (0%)0/10 (0%)2/10 (20%)
Group C: BLV 10 mg, Matched Control0/10 (0%)0/10 (0%)2/10 (20%)
Group D: BLV 10 mg, Severe Hepatic Impairment0/8 (0%)0/8 (0%)2/8 (25%)
Group D: BLV 10 mg, Matched Control0/8 (0%)0/8 (0%)2/8 (25%)
Most frequent other events
Showing 10 of 16
Most frequent other events
EventGroup A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched Control
Alanine aminotransferase increasedInvestigations0/110/110/80/80/102/100/80/8
Abdominal painGastrointestinal disorders0/110/111/80/80/100/100/80/8
Peripheral swellingGeneral disorders0/110/110/80/80/100/101/80/8
PyrexiaGeneral disorders0/110/110/81/80/100/100/80/8
Blood creatinine increasedInvestigations0/110/110/80/80/100/101/80/8
Electrocardiogram QT prolongedInvestigations0/110/111/80/80/100/100/80/8
Transaminases increasedInvestigations0/110/110/80/80/100/100/81/8
DizzinessNervous system disorders0/110/111/80/80/100/101/80/8
HeadacheNervous system disorders1/110/110/80/80/100/100/81/8
ConstipationGastrointestinal disorders0/110/110/80/81/100/100/80/8

Baseline characteristics

The Safety Analysis Set included all participants who took at least 1 dose of study drug BLV.

Age, Categorical
Age, Categorical(Participants)Group A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched ControlTotal
<=18 years000000000
Between 18 and 65 years71077788761
>=65 years4111320113
Age, Continuous
Age, Continuous(years)Group A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched ControlTotal
Mean59 ± 10.556 ± 7.447 ± 12.546 ± 12.761 ± 7.459 ± 6.052 ± 7.753 ± 8.655 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Group A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched ControlTotal
Female3344333326
Male8844775548
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched ControlTotal
Hispanic or Latino7757866652
Not Hispanic or Latino4431242222
Unknown or Not Reported000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched ControlTotal
American Indian or Alaska Native000000000
Asian000000000
Native Hawaiian or Other Pacific Islander000000000
Black or African American120001026
White109881098668
More than one race000000000
Unknown or Not Reported000000000
Region of Enrollment
Region of Enrollment(Participants)Group A: BLV 2 mg, Moderate Hepatic ImpairmentGroup A: BLV 2 mg, Matched ControlGroup B: BLV 2 mg, Severe Hepatic ImpairmentGroup B: BLV 2 mg, Matched ControlGroup C: BLV 10 mg, Moderate Hepatic ImpairmentGroup C: BLV 10 mg, Matched ControlGroup D: BLV 10 mg, Severe Hepatic ImpairmentGroup D: BLV 10 mg, Matched ControlTotal
United States11118810108874
08

Study locations

6 sites
  • Orange County Research Center
    Lake Forest, California 92630, United States
  • Clinical Pharmacology of Miami, LLC
    Miami, Florida 33014, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research LLC
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Kumar P, Mercier RC, Nieves W, Pan D, Tseng S, Chee GM, et al. Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 2 mg Once Daily for 6 Days in Participants With Moderate and Severe HI and in Matched Control Participants With Normal Hepatic Function. American Association for the Study of Liver Diseases (AASLD); 1154: 15 November 2024
  • Parag Kumar, Wildaliz Nieves, David Pan, Steve Tseng, Yuejiao Jiang, Yehong Wang, Ann Qin, Teckla Akinyi, Renee-Claude Mercier. Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 10 mg Once Daily for 6 Days in Participants With Moderate HI and in Matched Control Participants With Normal Hepatic Function. EASL - European Association for the Study of the Liver May 7-10, 2025 Amsterdam the Netherlands

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Jan 2025, 21 months.

Results were first posted in Jan 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2023
First posted
Mar 13, 2023
StartActual
Mar 15, 2023
Primary completionActual
Jan 10, 2025
CompletionActual
Jan 13, 2025
Results first posted
Jan 26, 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05765344
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 13, 2023
Start date
Mar 15, 2023
Primary completion
Jan 10, 2025
Completion
Jan 13, 2025
Results posted
Jan 26, 2026
Last update
Jan 26, 2026

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bulevirtide

Start the discussion